Ionis Pharmaceuticals IONS Stock issued during period, value, long-term incentive plan activity
Stock issued during period, value, long-term incentive plan activity at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's stock issued during period, value, long-term incentive plan activity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's stock issued during period, value, long-term incentive plan activity?
- Ionis Pharmaceuticals (IONS) reported stock issued during period, value, long-term incentive plan activity of $57.3M in Q1 2026.
- How has Ionis Pharmaceuticals's stock issued during period, value, long-term incentive plan activity changed year-over-year?
- Ionis Pharmaceuticals's stock issued during period, value, long-term incentive plan activity increased by 2455.8% year-over-year, from $2.24M to $57.3M.
- What is the long-term trend for Ionis Pharmaceuticals's stock issued during period, value, long-term incentive plan activity?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's stock issued during period, value, long-term incentive plan activity has grown at a 97.4% compound annual growth rate (CAGR), from $49.44M to $192.6M.
- What does stock issued during period, value, long-term incentive plan activity mean?
- The total dollar value of stock granted to employees as compensation.
- How do you interpret stock issued during period, value, long-term incentive plan activity?
- An increase suggests higher reliance on equity-based incentives, which may signal dilution for existing shareholders but preserves cash for R&D.
- How does stock issued during period, value, long-term incentive plan activity compare across companies?
- Common in high-growth biotech firms to manage cash burn while attracting top scientific talent.